Your GLP-1 Is Doing More to Your Brain Than You Think

Your brain runs on a currency called dopamine, and that currency does not just control how good things feel. It controls whether you pursue them in the first place.

That distinction matters more than most people realize, and it sits at the center of what GLP-1 drugs are actually doing inside your skull.

Here is the full chain before we zoom in. You eat food, your gut releases GLP-1, which is a hormone that signals satiety and slows digestion. Pharmaceutical GLP-1 receptor agonists like semaglutide or retatrutide mimic that signal at a much higher magnitude and for a much longer duration than your body would ever produce naturally. The target most people know about is the hypothalamus, where appetite gets suppressed. But GLP-1 receptors are not only in the hypothalamus. They sit in a structure deep in the brainstem called the ventral tegmental area, or VTA, which is the origin point of your brain's entire reward and motivation circuit.

That is the part people are not being told about.

The VTA contains two populations of neurons that work in opposition to each other. Dopamine neurons are the ones that generate wanting, the drive to move toward something, to initiate, to seek. GABA neurons sit alongside them and act as an inhibitory brake on dopamine activity. When GLP-1 receptors in the VTA get activated, research published in Science Advances in 2025 showed they increase the firing rate of those GABA neurons, which then suppress dopamine neuron activity. The gas pedal gets less fuel because someone is riding the brake harder.

This is not a subtle effect. The same study found that this circuit, when activated by endogenous GLP-1, reduced cocaine-seeking behavior in animal models, which tells you the magnitude of the reward suppression is strong enough to blunt one of the most powerful dopamine signals researchers can produce in a lab setting.

Now here is where the science gets genuinely counterintuitive.

Researchers have found that GLP-1 agonists reduce something called "wanting," which is the anticipatory drive to pursue a reward, without meaningfully reducing something called "liking," which is the hedonic pleasure you experience once you receive it. A 2025 study on semaglutide found that while the drug reduced reward-collection behavior, it actually enhanced VTA dopamine activity during the consummatory phase, meaning the moment of actually getting the reward. The seeking goes down. The enjoyment does not.

Think about what that means in practice. If the drug suppressed both wanting and liking, you would notice. You would feel flat. Things that used to feel good would feel empty, and that gap would register as something being wrong. But when only wanting is suppressed, nothing feels wrong in the moment. Sex still feels good when it happens. Food that you do eat still tastes fine. You just stop initiating, stop thinking about it, stop reaching for things, and because every individual experience remains intact, your brain generates no signal that anything has changed.

That is the mechanism behind why people do not notice until they come off the drug and the drive returns.

There is a second pathway running in parallel to this one. A 2025 clinical review published in Obesity Pillars proposed that GLP-1 agonists also upregulate activity at a serotonin receptor called 5-HT2C, which is the same receptor implicated in the sexual side effects of SSRI antidepressants. SSRIs are well-documented to reduce libido and desire through this pathway, and the proposed mechanism here is biologically identical. So you may have dopamine suppression coming from the VTA GABA circuit on one side, and serotonergic dampening of desire from 5-HT2C upregulation on the other side, both operating simultaneously, both pointing in the same direction.

The review also noted something worth understanding about why this goes undetected clinically. GLP-1 drugs produce weight loss, and weight loss independently improves mood, body image, and sexual confidence. Those positive psychological effects can partially mask the neurochemical suppression happening underneath, so even when someone reports their sex life is fine on GLP-1s, the competing variables make it genuinely difficult to separate the signal from the noise.

A randomized controlled trial on dulaglutide in healthy men found no significant change in sexual function scores over four weeks, which is often cited as reassuring, but dulaglutide has weaker central nervous system penetration than semaglutide and the study duration was short, so the null result may say more about the specific compound and timeframe than about the class as a whole.

The alcohol research adds a useful confirmation. A 2025 randomized clinical trial published in JAMA Psychiatry put 48 adults with alcohol use disorder on once-weekly semaglutide and found significant reductions in alcohol craving, consumption, and heavy drinking days. Alcohol, sex, food, and substances all converge on the same mesolimbic dopamine system, so when you see one category of reward-seeking behavior reliably suppressed across multiple clinical trials, it strongly suggests a broad change in how the brain is weighting and pursuing all categories of reward, not a targeted effect on appetite alone.

On reversibility: semaglutide has a half-life of approximately one week, so within four to five weeks of stopping the drug, plasma levels reach near-zero and receptor signaling returns toward baseline. The reward suppression appears to be state-dependent on the drug's presence rather than a lasting structural change, though long-term data on full motivational recovery are still limited.

If you are using one of these compounds and you have noticed that you are less interested in sex, or less interested in hobbies, or less likely to initiate things you used to pursue without thinking, the mechanism above is the reason. And if your partner has noticed before you have, that is not a coincidence. That is exactly what wanting-without-liking suppression looks like from the outside.

The practical implication is simple: if libido or motivation matters to you while on a GLP-1, that is a variable worth tracking deliberately, because the drug will not give you a signal that it is changing, and neither will your own experience of the moments when nothing is actually wrong.

The drugs are doing exactly what they are designed to do. Reducing pursuit of rewarding stimuli is the mechanism. Food is just the reward category the marketing focuses on.

---

References

1. Merkel R, Thapa N, Engel L, et al. 2025. An endogenous GLP-1 circuit engages VTA GABA neurons to regulate mesolimbic dopamine neurons and attenuate cocaine seeking. Science Advances, 119, eadr5051. Finding: GLP-1 receptor activation in the VTA increases GABA neuron firing, which suppresses dopamine neuron activity and reduces reward-seeking behavior. Source
2. Hurst K, et al. 2025. GLP-1 receptor agonist semaglutide reduces appetite while increasing dopamine reward signaling. Neurobiology of Disease and Treatment. Finding: Semaglutide reduced reward collection but did not diminish hedonic "liking" response, and actually enhanced VTA dopamine activity during consummatory phase. Source
3. Gelfand SG, Tveit RL, Simon JA. 2026. Clinical review of how glucagon-like peptide-1 agonist obesity medications decrease sexual desire, and a biopsychosocial model for why we don't 'see' it. Obesity Pillars, 17, 100233. Finding: GLP-1 agonists likely decrease sexual desire via 5-HT2C serotonergic upregulation same mechanism as SSRIs, but this is camouflaged by competing positive effects of weight loss. Source
4. Hendershot CS, et al. 2025. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 824, 395-405. Finding: Semaglutide reduced alcohol consumption, craving, and heavy drinking days in a Phase 2 RCT n=48, confirming reward pathway modulation extends beyond appetite. Source
5. Jalleh RJ, et al. 2024. Effects of the glucagon-like peptide-1 receptor agonist dulaglutide on sexuality in healthy men: a randomised, double-blind, placebo-controlled crossover study. eBioMedicine, 107. Finding: 4-week dulaglutide in healthy eugonadal men showed no change in sexual function scores null result, but short duration and weaker CNS penetration than semaglutide. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness